TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30243304

Group type: EXPERIMENTAL
Intervention: Extubation failure (defined as need for reintubation within 48 hours)
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Intubation for coma
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Intubation for acute respiratory failure
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Absence of strong cough
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Length of ventilation > 8 days
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Copious secretions
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: Non-obese status
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: SOFA score ≥ 8
Number of subjects: 1514

Group type: EXPERIMENTAL
Intervention: ICU mortality
Number of subjects: 1514
Study: 30243412

Group type: EXPERIMENTAL
Intervention: Contingency management with financial incentives
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Contingency management for substance use-related behaviors
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall inclusion of contingency management
Number of subjects: 22
Study: 30243418

Group type: EXPERIMENTAL
Intervention: Buprenorphine (various formulations: oral, injection, implant)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Daily buprenorphine formulations (tablet or film)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Weekly or monthly injection
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Bi-annual implant
Number of subjects: 338

Group type: COMPARATOR
Intervention: Past buprenorphine prescription
Number of subjects: 338
Study: 30243566

Group type: EXPERIMENTAL
Intervention: TUS examination pre-talc and post-talc instillation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TUS scoring by independent assessors
Number of subjects: 18
Study: 30243800

Group type: EXPERIMENTAL
Intervention: Durvalumab alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with Tremelimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30243817

Group type: EXPERIMENTAL
Intervention: All-night fMRI sleep studies on Night 2
Number of subjects: 12
Study: 30244023

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30244099

Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 9

Group type: COMPARATOR
Intervention: Autologous control subjects
Number of subjects: 9
Study: 30244215

Group type: EXPERIMENTAL
Intervention: Disclosure to contacts
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Testing of contacts
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Results received by contacts
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: HBsAg-positive results among tested contacts
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Factors associated with disclosure
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Barriers to disclosure and testing
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Association with HIV-related stigma
Number of subjects: 79
Study: 30244344

Group type: EXPERIMENTAL
Intervention: Robotic assisted transabdominal retromuscular umbilical prosthetic repair (r-TARUP) using a 15×15 cm self-fixating mesh
Number of subjects: 41
Study: 30244381

Group type: EXPERIMENTAL
Intervention: Forearm post-ischemic flow-mediated vasodilation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Skin microvascular reactivity (sodium nitroprusside)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Skin microvascular reactivity (heating)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pulse wave reflection changes
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Subendocardial viability ratio
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Endothelial function indices
Number of subjects: 71
Study: 30244613

Group type: EXPERIMENTAL
Intervention: Brexpiprazole as adjunctive treatment
Number of subjects: 0
Study: 30244975

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study: 30245150

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30245163

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of nucleus accumbens (NAc) and anterior limb of the internal capsule (ALIC)
Number of subjects: 8
Study: 30245189

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (20 mg twice daily)
Number of subjects: 19
Study: 30245572

Group type: EXPERIMENTAL
Intervention: PEEP optimization using esophageal balloon (ESO Group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Best achieved static effective compliance (Cstat Group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ESO Group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cstat Group
Number of subjects: 25
Study: 30245644

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 30245839

Group type: EXPERIMENTAL
Intervention: Right ventricular myo-mechanical index (RV-MMI)
Number of subjects: 65
Study: 30245866

Group type: EXPERIMENTAL
Intervention: HIV service integration with family planning (FP) in 6 of 12 facilities; intervention period: 2009-2012.
Number of subjects: 25539

Group type: COMPARATOR
Intervention: HIV-postnatal care intervention in 2009-2010; half the facilities received this intervention.
Number of subjects: 25539

Group type: EXPERIMENTAL
Intervention: HIV counselling provided alongside RH services.
Number of subjects: 25539
Study: 30246149

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg twice daily
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 30246234

Group type: EXPERIMENTAL
Intervention: Esophagus temperature measurement
Number of subjects: 36

Group type: COMPARATOR
Intervention: Urinary bladder temperature measurement
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both sites (esophagus and urinary bladder)
Number of subjects: 36
Study: 30246437

Group type: EXPERIMENTAL
Intervention: Early childcare enrollment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30246613

Group type: EXPERIMENTAL
Intervention: In-person CI therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Video-game home-based CI therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study: 30246793

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30247091

Group type: EXPERIMENTAL
Intervention: Intense locomotor treadmill training with weight support and simultaneous spinal cord epidural stimulation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (locomotor training alone)
Number of subjects: 4
Study: 30247434

Group type: EXPERIMENTAL
Intervention: Self-reported habitual physical activity
Number of subjects: 46
Study: 30247611

Group type: EXPERIMENTAL
Intervention: 5% increase in energy from saturated fatty acid (SFA)
Number of subjects: 121335

Group type: EXPERIMENTAL
Intervention: 1% increase in energy from trans-fat
Number of subjects: 121335

Group type: EXPERIMENTAL
Intervention: 5% increase in energy from polyunsaturated fatty acid (PUFA)
Number of subjects: 121335

Group type: EXPERIMENTAL
Intervention: 1% increase in intake of monounsaturated fatty acid (MUFA) from animal sources
Number of subjects: 121335

Group type: EXPERIMENTAL
Intervention: MUFA from plant sources
Number of subjects: 121335
Study: 30247646

Group type: EXPERIMENTAL
Intervention: Secretor mothers (presence of 2'-fucosylactose)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Seasonal and geographic variation
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Parity, ethnicity, and breastfeeding exclusivity
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Earlier breastfeeding cessation
Number of subjects: 427
Study: 30247752

Group type: EXPERIMENTAL
Intervention: Customized three-dimensional-printed nasal silicone stent implanted for 2 months
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Customized three-dimensional-printed nasal silicone stent
Number of subjects: 1
Study: 30248151

Group type: EXPERIMENTAL
Intervention: Tele-expertise in dermatology
Number of subjects: 450

Group type: COMPARATOR
Intervention: Face-to-face consultation (control)
Number of subjects: 450
Study: 30248632

Group type: EXPERIMENTAL
Intervention: BD-NP (n=38)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: BD-P (n=49)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Comp (n=87)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: BD-NP
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: BD-P
Number of subjects: 174
Study: 30249192

Group type: EXPERIMENTAL
Intervention: Total-P16M-positive patients
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: P16H-positive OEDs
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: True-P16M-positive OEDs
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: P16H and true-P16M
Number of subjects: 265
Study: 30249277

Group type: EXPERIMENTAL
Intervention: Vismodegib (150 mg/day orally) and Ruxolitinib (15 or 20 mg orally twice daily)
Number of subjects: 10
Study: 30249279

Group type: EXPERIMENTAL
Intervention: MySafeRx platform
Number of subjects: 12
Study: 30249293

Group type: EXPERIMENTAL
Intervention: Peer-based sleep health education and social support
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 398
Study: 30249388

Group type: EXPERIMENTAL
Intervention: HXTCs (HIV-specific T cells)
Number of subjects: 0
Study: 30249629

Group type: EXPERIMENTAL
Intervention: Supplementary material (additional data tables)
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Supplementary material (checklists and reporting guidelines)
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Publication of additional tables and figures on the journal's website
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Availability of raw study data on the journal's website
Number of subjects: 2872
Study: 30249633

Group type: EXPERIMENTAL
Intervention: Training for performing the study
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Presentation of the study
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Obtaining consent, data collection, and entry
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Support from the coordinating study centre
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Scientific relevance of the DACAPO study
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Value of study results for improving patient care
Number of subjects: 169
Study: 30250733

Group type: EXPERIMENTAL
Intervention: Endotoxin core antibody levels (EndoCAb)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Staphylococcal antibody levels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antibodies to varicella
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-operative length of stay (LOS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Development of infective complications
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Length of stay on the intensive care unit (ICU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30-day mortality
Number of subjects: 60
Study: 30251145

Group type: EXPERIMENTAL
Intervention: T cell receptor excision circle (TREC) assay
Number of subjects: 200000
Study: 30251913

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (aHSCT)
Number of subjects: 23
Study: 30252100

Group type: COMPARATOR
Intervention: Women
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 60
Study: 30252603

Group type: EXPERIMENTAL
Intervention: Hib-MenCY-TT
Number of subjects: 600

Group type: COMPARATOR
Intervention: Hib-OMP
Number of subjects: 600
Study: 30252856

Group type: EXPERIMENTAL
Intervention: Oral ivermectin at a dose of 200 micrograms per kilogram administered on day 1 and day 8
Number of subjects: 118
Study: 30253140

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0
Study: 30253758

Group type: EXPERIMENTAL
Intervention: targeted PITC (tPITC)
Number of subjects: 4719

Group type: COMPARATOR
Intervention: blanket PITC (bPITC)
Number of subjects: 4719
Study: 30253804

Group type: EXPERIMENTAL
Intervention: AMG 228 (1200 mg, administered intravenously every 3 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMG 228 (180-1200 mg, administered intravenously every 3 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMG 228 (doses > 360 mg, administered intravenously every 3 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMG 228 (monotherapy)
Number of subjects: 30
Study: 30253883

Group type: EXPERIMENTAL
Intervention: Superolateral Medial Forebrain Bundle Deep Brain Stimulation (DBS)
Number of subjects: 0
Study: 30254079

Group type: EXPERIMENTAL
Intervention: Blinatumomab (Blincyto; Amgen, Inc.)
Number of subjects: 86
Study: 30254130

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg/d
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ibrutinib 280 mg/d
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ibrutinib 140 mg/d
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ibrutinib (all doses)
Number of subjects: 11
Study: 30254139

Group type: EXPERIMENTAL
Intervention: Therapeutic bronchoscopy
Number of subjects: 102
Study: 30254189

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily
Number of subjects: 6
Study: 30254242

Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 846

Group type: COMPARATOR
Intervention: 24-hour recalls (24hR)
Number of subjects: 846
Study: 30254761

Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: At-home finger-stick tests for NGS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical circumstances and laboratory methods for AATD tests
Number of subjects: 0
Study: 30255316

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30255476

Group type: EXPERIMENTAL
Intervention: Tolvaptan combined with torasemide (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Torasemide monotherapy (control group, n=20)
Number of subjects: 40
Study: 30255800

Group type: EXPERIMENTAL
Intervention: Myoelectric prosthesis with pattern recognition control system
Number of subjects: 9
Study: 30255862

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 3686

Group type: EXPERIMENTAL
Intervention: ROMEO score of zero
Number of subjects: 3686
Study: 30256541

Group type: EXPERIMENTAL
Intervention: Gedatolisib (89 mg, intravenous infusion)
Number of subjects: 6
Study: 30256767

Group type: EXPERIMENTAL
Intervention: Airway Fractal Dimension (AFD) measurement
Number of subjects: 8135

Group type: EXPERIMENTAL
Intervention: Participants with AFD below median and peribronchial emphysema above median
Number of subjects: 8135
Study: 30256845

Group type: EXPERIMENTAL
Intervention: Sepsis on admission
Number of subjects: 4989

Group type: EXPERIMENTAL
Intervention: Blood culture positive for pathogenic organisms
Number of subjects: 4989

Group type: EXPERIMENTAL
Intervention: Transfer from other hospitals
Number of subjects: 4989

Group type: COMPARATOR
Intervention: Sepsis patients
Number of subjects: 4989

Group type: COMPARATOR
Intervention: Non-sepsis patients
Number of subjects: 4989
Study: 30256893

Group type: EXPERIMENTAL
Intervention: Lipid-rich test meal containing 20 mg [13C-10]-β-carotene
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lipid-rich control meal
Number of subjects: 10
Study: 30256903

Group type: EXPERIMENTAL
Intervention: Neurologic symptomatic cryptococcal antigenemia with negative CSF CrAg
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Cryptococcal meningitis (CSF CrAg+ positive)
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: CSF CrAg-negative patients
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: CSF culture and PCR testing
Number of subjects: 1201
Study: 30256905

Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine (RZV)
Number of subjects: 401
Study: 30256977

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 10
Study: 30257072

Group type: EXPERIMENTAL
Intervention: PCP-I
Number of subjects: 80

Group type: COMPARATOR
Intervention: PCP-C
Number of subjects: 80
Study: 30257076

Group type: EXPERIMENTAL
Intervention: Lean-body-weight-based dosing of pantoprazole (1.2 mg/kg)
Number of subjects: 62
Study: 30257699

Group type: EXPERIMENTAL
Intervention: Multidimensional prediction model for rupture risk of unruptured intracranial aneurysms (UIAs) based on hemodynamic factors, HRMRI findings, genetic factors, and biomarkers.
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: CIAP-2 study cohort of 500 patients with UIA.
Number of subjects: 5000
Study: 30257974

Group type: EXPERIMENTAL
Intervention: NAFLD-IR (lipid overload)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Humans (ventricle biopsies)
Number of subjects: 0
Study: 30258442

Group type: EXPERIMENTAL
Intervention: Low-Dose Mycophenolate Mofetil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30258648

Group type: EXPERIMENTAL
Intervention: Thiamine 500 mg oral capsule once daily for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiamine 500 mg oral capsule once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30258650

Group type: EXPERIMENTAL
Intervention: Kusamala Program
Number of subjects: 30
Study: 30258647

Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30259313

Group type: EXPERIMENTAL
Intervention: Everolimus and Exemestane
Number of subjects: 44
Study: 30260393

Group type: EXPERIMENTAL
Intervention: Overfeeding (+760 kcal/d) for 56 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Baseline measurements before intervention
Number of subjects: 26
Study: 30260396

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Insulin-modified frequently sampled intravenous glucose test (IM-FSIGT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT)
Number of subjects: 119
Study: 30260412

Group type: EXPERIMENTAL
Intervention: Fidaxomicin, 200 mg twice daily for 10 days
Number of subjects: 25
Study: 30260415

Group type: EXPERIMENTAL
Intervention: Propofol infusions (10 sessions, dosed to suppress EEG activity for 15 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (20 patients)
Number of subjects: 10
Study: 30260797

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not treated with TDF)
Number of subjects: 2
Study: 30261236

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (within PCI)
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Composite outcome (death, Q-wave myocardial infarction, or stroke)
Number of subjects: 2240
Study: 30261303

Group type: EXPERIMENTAL
Intervention: Acute EBV infection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 200
Study: 30261487

Group type: EXPERIMENTAL
Intervention: Home sleep apnea testing (HSAT)
Number of subjects: 83
Study: 30261902

Group type: EXPERIMENTAL
Intervention: Combination ART
Number of subjects: 800
Study: 30261899

Group type: EXPERIMENTAL
Intervention: SCID-X1 gene therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 30261907

Group type: EXPERIMENTAL
Intervention: Neuropathic-like knee pain (NKP)
Number of subjects: 9506

Group type: COMPARATOR
Intervention: Fibromyalgia
Number of subjects: 9506

Group type: COMPARATOR
Intervention: Widespread pain
Number of subjects: 9506

Group type: COMPARATOR
Intervention: Nodal osteoarthritis
Number of subjects: 9506

Group type: COMPARATOR
Intervention: Significant knee injury
Number of subjects: 9506

Group type: COMPARATOR
Intervention: Pain catastrophising
Number of subjects: 9506

Group type: COMPARATOR
Intervention: Fatigue
Number of subjects: 9506

Group type: COMPARATOR
Intervention: Central risk factors
Number of subjects: 9506

Group type: COMPARATOR
Intervention: Central and peripheral risk factors
Number of subjects: 9506
Study: 30261995

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 μg
Number of subjects: 9942

Group type: COMPARATOR
Intervention: tiotropium 5 μg
Number of subjects: 9942

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol
Number of subjects: 9942

Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 9942
Study: 30262187

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 792

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m²
Number of subjects: 792
Study: 30262655

Group type: EXPERIMENTAL
Intervention: Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield)
Number of subjects: 50
Study: 30262657

Group type: EXPERIMENTAL
Intervention: Versi Retriever
Number of subjects: 11
Study: 30262659

Group type: EXPERIMENTAL
Intervention: Pomalidomide (POM) 5 mg daily for 21 days every 28 days and Dexamethasone (DEX) 40 mg orally every week
Number of subjects: 29
Study: 30262660

Group type: EXPERIMENTAL
Intervention: Donor-derived LMP-specific T cells (LMP-Ts)
Number of subjects: 26
Study: 30263228

Group type: EXPERIMENTAL
Intervention: Schizophrenia Oral Health Profile (SOHP) questionnaire
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews and focus groups
Number of subjects: 30
Study: 30263981

Group type: EXPERIMENTAL
Intervention: Perioperative liver function tests using LiMAx
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard care without LiMAx testing
Number of subjects: 148
Study: 30264504

Group type: EXPERIMENTAL
Intervention: Systemic therapy for advanced or metastatic NSCLC
Number of subjects: 0
Study: 30264864

Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate 50 or 100 mg twice daily for 8 years
Number of subjects: 26
Study: 30265059

Group type: EXPERIMENTAL
Intervention: Social network characteristics and perceived peer drinking norms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived peer drinking norms
Number of subjects: 0